MX2009013740A - Derivados de tiazol fusionados como inhibidores de cinasa. - Google Patents

Derivados de tiazol fusionados como inhibidores de cinasa.

Info

Publication number
MX2009013740A
MX2009013740A MX2009013740A MX2009013740A MX2009013740A MX 2009013740 A MX2009013740 A MX 2009013740A MX 2009013740 A MX2009013740 A MX 2009013740A MX 2009013740 A MX2009013740 A MX 2009013740A MX 2009013740 A MX2009013740 A MX 2009013740A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
thiazole derivatives
fused thiazole
substituted
derivatives
Prior art date
Application number
MX2009013740A
Other languages
English (en)
Inventor
Richard Jeremy Franklin
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile Crepy
Anne Marie Foley
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Priority claimed from PCT/GB2008/002194 external-priority patent/WO2009001089A1/en
Publication of MX2009013740A publication Critical patent/MX2009013740A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una serie de derivados de 6,7-dihidro[1,3]tiazolo[5,4-c]piridin-4( 5H)-ona, que se sustituyen en la posición 2 por un resto morfolin-4-ilo sustituido, que son inhibidores selectivos de enzimas PI3 cinasa, y son, por lo tanto beneficiosos en medicina, por ejemplo en el tratamiento de afecciones inflamatorias, autoinmunes, cardiovasculares, neurodegenerativas, metabólicas, oncológicas, nociceptivas u oftalmológicas.
MX2009013740A 2006-06-26 2008-06-24 Derivados de tiazol fusionados como inhibidores de cinasa. MX2009013740A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors
PCT/GB2008/002194 WO2009001089A1 (en) 2007-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009013740A true MX2009013740A (es) 2010-02-01

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013740A MX2009013740A (es) 2006-06-26 2008-06-24 Derivados de tiazol fusionados como inhibidores de cinasa.

Country Status (20)

Country Link
US (3) US8242116B2 (es)
EP (2) EP2035436B1 (es)
CN (1) CN101687885B (es)
AT (1) ATE510840T1 (es)
AU (1) AU2008269577B2 (es)
CA (1) CA2692085C (es)
CO (1) CO6270229A2 (es)
CY (1) CY1114419T1 (es)
DK (1) DK2170906T3 (es)
EA (1) EA017187B1 (es)
ES (2) ES2365258T3 (es)
HR (1) HRP20130523T1 (es)
IL (1) IL202659A0 (es)
ME (1) ME01592B (es)
MX (1) MX2009013740A (es)
MY (1) MY148852A (es)
PL (1) PL2170906T3 (es)
PT (1) PT2170906E (es)
RS (1) RS52824B (es)
WO (1) WO2008001076A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
WO2010011871A2 (en) * 2008-07-23 2010-01-28 The Regents Of The University Of California Methods and compositions for providing salicylic acid-independent pathogen resistance in plants
JPWO2010027002A1 (ja) * 2008-09-05 2012-02-02 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
EP2398810A1 (en) 2009-02-17 2011-12-28 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
CA2755253A1 (en) * 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5554833B2 (ja) 2009-05-20 2014-07-23 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
CA2771594C (en) 2009-08-20 2018-05-01 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
SG181715A1 (en) 2009-12-18 2012-07-30 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
JP5763672B2 (ja) 2009-12-18 2015-08-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール
BR112012032259A2 (pt) 2010-06-15 2015-09-15 Bayer Ip Gmbh "novos derivados de arilamida orto-substituída".
JP2013540115A (ja) 2010-10-01 2013-10-31 ビーエーエスエフ ソシエタス・ヨーロピア イミン化合物
AR083450A1 (es) * 2010-10-13 2013-02-27 Millennium Pharm Inc Heteroarilos y sus usos en el tratamiento de enfermedades proliferativas, inflamatorias o cardiovasculares
MX2013005825A (es) * 2010-11-24 2013-08-27 Exelixis Inc Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
CA2830516C (en) 2011-03-23 2017-01-24 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EA030481B1 (ru) 2013-03-14 2018-08-31 Эпизим, Инк. Ингибиторы аргининметилтрансферазы и их применения
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9776972B2 (en) 2013-03-14 2017-10-03 Epizyme Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160257650A1 (en) * 2013-10-21 2016-09-08 Umicore Ag & Co. Kg Monoarylation of aromatic amines
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
TW202039473A (zh) 2018-12-19 2020-11-01 丹麥商理奧藥品公司 Il-17的小分子調節劑
AR119672A1 (es) * 2019-01-08 2022-01-05 Kyorin Seiyaku Kk Inhibidor de 15-pgdh

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
CA2692085C (en) 2015-10-13
US8710054B2 (en) 2014-04-29
CN101687885B (zh) 2012-08-22
CA2692085A1 (en) 2008-12-31
ES2416364T3 (es) 2013-07-31
PL2170906T3 (pl) 2013-08-30
CY1114419T1 (el) 2016-08-31
EA017187B1 (ru) 2012-10-30
RS52824B (es) 2013-10-31
MY148852A (en) 2013-06-14
EP2170906B1 (en) 2013-04-03
AU2008269577B2 (en) 2012-12-20
CN101687885A (zh) 2010-03-31
EA201000038A1 (ru) 2010-06-30
ME01592B (me) 2014-09-20
ES2365258T3 (es) 2011-09-27
ATE510840T1 (de) 2011-06-15
US8338592B2 (en) 2012-12-25
HRP20130523T1 (en) 2013-07-31
EP2170906A1 (en) 2010-04-07
EP2035436B1 (en) 2011-05-25
DK2170906T3 (da) 2013-06-24
EP2035436A1 (en) 2009-03-18
WO2008001076A1 (en) 2008-01-03
PT2170906E (pt) 2013-06-25
US20110003785A1 (en) 2011-01-06
US20130079330A1 (en) 2013-03-28
IL202659A0 (en) 2010-06-30
CO6270229A2 (es) 2011-04-20
AU2008269577A1 (en) 2008-12-31
US20100137302A1 (en) 2010-06-03
US8242116B2 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
HRP20130523T1 (en) Fused thiazole derivatives as kinase inhibitors
GB0508471D0 (en) Therapeutic agents
NO20083739L (no) Tieno-pyridinderivater som MEK-inhibitorer
WO2010052448A3 (en) Fused pyrazine derivatives as kinase inhibitors
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
WO2006098961A3 (en) Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
TN2018000416A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
AP2011005975A0 (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors.
CL2008003280A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
HK1134486A1 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4,3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders plk1 45--[124][43- f]
IL181387A0 (en) Fused tricyclic derivatives for the treatment of psychotic disorders
ZA201100437B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
EP3976607A4 (en) SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINAS INHIBITORS
IL280513A (en) Imidazo[2,1-B]pyridazines as TRK inhibitors
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы
IL299758A (en) History of 7-(piperidin-1-yl)-4H-pyrimidio[2,1-B]pyridazin-4-one as positive allosteric modulators of the M4 muscarinic acetylcholine receptor
EP3851439A4 (en) BTK INHIBITOR CONTAINING FURO[3,4-B]PYRROLE
SG11202100337RA (en) Imidazo[1,2-b]pyridazine derivatives as trk inhibitors
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
DOP2009000289A (es) Derivados de tiazol fusionados como inhibidores de quinasa
MX2019013518A (es) Formas cristalinas de seletalisib.

Legal Events

Date Code Title Description
FG Grant or registration